Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: motor neuron disease gene therapy - Oxford BioMedica

Drug Profile

Research programme: motor neuron disease gene therapy - Oxford BioMedica

Alternative Names: Amyotrophic lateral sclerosis gene therapy - Oxford BioMedica; MoNuDin; OXB-103; SMN-1G; Spinal muscular atrophy gene therapy - Oxford BioMedica

Latest Information Update: 24 Oct 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Oxford BioMedica; The Cleveland Clinic Foundation
  • Developer Oxford BioMedica
  • Class Gene therapies; Spinal muscular atrophy gene therapies
  • Mechanism of Action Gene transference; Survival of motor neuron 1 protein expression stimulants; Vascular endothelial growth factor A expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Amyotrophic lateral sclerosis; Motor neuron disease

Highest Development Phases

  • Preclinical Amyotrophic lateral sclerosis
  • Discontinued Spinal muscular atrophy

Most Recent Events

  • 24 Oct 2018 Preclinical development in Amyotrophic lateral sclerosis is ongoing in United Kingdom (Oxford BioMedica pipeline, October 2018)
  • 24 Oct 2018 Discontinued - Preclinical for Spinal muscular atrophy in United Kingdom (IM)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in United Kingdom (IM, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top